Dyadic International (NASDAQ:DYAI – Get Free Report) and Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Dyadic International and Lisata Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dyadic International | 1 | 0 | 1 | 0 | 2.00 |
| Lisata Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 629.75%. Given Dyadic International’s stronger consensus rating and higher possible upside, research analysts clearly believe Dyadic International is more favorable than Lisata Therapeutics.
Profitability
This table compares Dyadic International and Lisata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dyadic International | -201.43% | -2,920.31% | -84.77% |
| Lisata Therapeutics | N/A | -116.08% | -90.55% |
Earnings and Valuation
This table compares Dyadic International and Lisata Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dyadic International | $3.09 million | 5.33 | -$7.36 million | ($0.23) | -1.79 |
| Lisata Therapeutics | $170,000.00 | 54.59 | -$16.59 million | ($1.64) | -0.63 |
Dyadic International has higher revenue and earnings than Lisata Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Dyadic International has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Insider & Institutional Ownership
27.9% of Dyadic International shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Dyadic International beats Lisata Therapeutics on 10 of the 14 factors compared between the two stocks.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
